FibroBiologics, Inc. (FBLG)
1.36
-0.07
(-4.90%)
USD |
NASDAQ |
Sep 21, 16:00
1.49
+0.13
(+9.56%)
After-Hours: 04:12
FibroBiologics Total Liabilities (Quarterly) : 3.293M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.293M |
| March 31, 2026 | 3.338M |
| December 31, 2025 | 13.21M |
| September 30, 2025 | 8.619M |
| June 30, 2025 | 13.05M |
| March 31, 2025 | 9.076M |
| December 31, 2024 | 19.39M |
| September 30, 2024 | 7.732M |
| Date | Value |
|---|---|
| June 30, 2024 | 11.30M |
| March 31, 2024 | 15.26M |
| December 31, 2023 | 10.57M |
| September 30, 2023 | 2.761M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 8.82M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 7.929M |
| Shareholders Equity (Quarterly) | 4.636M |
| Debt to Equity Ratio | 0.3154 |
| Current Ratio | 2.644 |
| Net Debt Paydown Yield | 19.62% |